ArticleSmart molecules : open access2024
A self-reinforced activatable photosensitizer prodrug enabling synergistic photodynamic and chemotherapy.
Article in Smart molecules : open access, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Smart mesoporous silica nanoparticles for precision cancer therapy: Tumor targeting and stimuli-responsive controlled release.Smart molecules : open access · 2026Review
- A photoimmune synergizing RNA interference technology for highly effective antitumor treatment.Smart molecules : open access · 2026Article
- Invoking ferroptosis and photon-controlled pyroptosisChemical science · 2026Article
- A single-molecule prodrug synergistically suppresses MYC-amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy.Smart molecules : open access · 2026Article
- Enhanced through-bond energy transfer-based bioorthogonal probe enables catalytic-amplified and sensitive detection of microRNA-21 for clinical lung cancer diagnosis.Smart molecules : open access · 2026Article
- Mechanism elucidation of cell-selective fluorescent probes.Smart molecules : open access · 2026Article
- Enhancing Tumor Photodynamic Therapy via Molecular Engineering and Functional Modification of Photosensitizers.Molecules (Basel, Switzerland) · 2026Review
- Recent Advances and Future Directions in 5-Fluorouracil Drug Delivery: A Comprehensive Review.Current topics in medicinal chemistry · 2026Review
- Bulky Group Shaping Cyanine as an Efficient Photosensitizer: A Photo-Inducer for Photodynamic Immunotherapy.JACS Au · 2025Article
- A recyclable type-I photosensitizer to enable red-light-driven gram-scale aerobic photocatalysis.Smart molecules : open access · 2025Article
- An activatable unimolecular phototheranostic agent for synergistic chemo-photodynamic therapy.Chemical science · 2025Article
- A self-reinforced activatable photosensitizer prodrug enabling synergistic photodynamic and chemotherapy.Smart molecules : open access · 2024Article
- Light-controlled smart materials: Supramolecular regulation and applications.Smart molecules : open access · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a novel drug development paradigm, selective activation of prodrugs provides the potential for precise tumor chemotherapy, thereby presenting an opportunity for advancing cancer treatment. The combination of photodynamic therapy (PDT) and prodrug can enhance the therapeutic efficacy while simultaneously enabling real-time monitoring of drug distribution and release. However, the tumor hypoxia microenvironment and the frequent high-dose administration of prodrugs significantly impede therapeutic efficacy and escalate treatment-related risks. Herein, a tumor microenvironment-specific release prodrug is constructed, termed NBS-2S-5FU. Under the influence of glutathione (GSH), NBS-2S-5FU undergoes activation, leading to the release of photosensitizer NBS and chemotherapeutic agent 5-FU derivatives. Under irradiation, NBS produces sufficient superoxide radical (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.